<DOC>
	<DOCNO>NCT00002086</DOCNO>
	<brief_summary>Primary : To determine whether combination zidovudine/zalcitabine/interferon alfa-n1 ( Retrovir/HIVID/Wellferon ) produce complete response ( i.e. , CD4 count return &gt; = 800 cells/mm3 24 week ) patient virus sensitive three agent . To determine antiviral effect combination therapy evidence measure quantitative viral load perform select study center . Secondary : To determine effectiveness Retrovir/HIVID Retrovir/HIVID/Wellferon maintain increase CD4 count prevent disease progression evidence development AIDS-defining indicator disease . To determine effect regimen secondary measure clinical status ( e.g. , performance score , weight change , secondary infection ) measure virologic activity serum p24 antigen . To assess safety tolerance regimen .</brief_summary>
	<brief_title>A Randomized Trial Evaluate Safety Efficacy Combination Therapy With Retrovir ( AZT ) HIVID ( ddC ) Versus Retrovir , HIVID , Wellferon ( Interferon Alfa-n1 ) Treatment HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection document licensed ELISA confirm Western blot ; OR positive HIV culture ; OR positive HIV antigen ; OR plasma viremia . CD4 count &gt; = 300 &lt; = 500 cells/mm3 two occasion within 30 day prior study entry . Patients &lt; 18 year age must write consent parent guardian . The effect combination therapy infant develop fetus unknown . Patients encourage utilize adequate contraception enrol study . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current AIDSdefining indicator disease , include opportunistic infection , AIDS dementia , AIDSwasting syndrome , AIDSassociated malignancy . Grade 2 bad peripheral neuropathy . Intolerance Retrovir 600 mg/day , HIVID 2.25 mg/day , interferonalfa product 3.0 MU/day . Significant cardiac dysfunction ( NYHA grade 3 4 ) . Concurrent Medication : Excluded : Chemotherapeutic agent 76 week follow study entry . Cardiac glycoside , antiarrhythmic , vasodilator . Patients follow prior condition exclude : History AIDSdefining indicator disease , include opportunistic infection , AIDS dementia , AIDSwasting syndrome , AIDSassociated malignancy . History grade 2 bad peripheral neuropathy . History intolerance Retrovir 600 mg/day , HIVID 2.25 mg/day , interferonalfa product 3.0 MU/day . Prior Medication : Excluded : More 3 month prior antiretroviral therapy . Cytotoxic chemotherapy within 4 week prior study entry . Immunomodulating agent systemic corticosteroid , IL2 , IFNalfa , IFNbeta within 4 week prior study entry . Cardiac glycoside , antiarrhythmic , vasodilator . Prior Treatment : Excluded : Radiation therapy within 4 week prior study entry . Current alcohol illicit drug use would interfere patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1993</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon-alpha</keyword>
</DOC>